MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bjh.15577

Медицинская библиотека · British journal of haematology · 2018

Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.

Héritier Sébastien, Barkaoui Mohamed-Aziz, Miron Jean, Thomas Caroline, Moshous Despina, Lambilliotte Anne, Mazingue Françoise, Kebaili Kamila, Jeziorski Eric, Plat Geneviève, Aladjidi Nathalie, Pacquement Hélène, Galambrun Claire, Brugières Laurence, Leverger Guy, Mansuy Ludovic, Paillard Catherine, Deville Anne, Pagnier Anne, Lutun Anne, Gillibert-Yvert Marion, Stephan Jean-Louis, Cohen-Aubart Fleur, Haroche Julien, Pellier Isabelle, Millot Fréderic, Gandemer Virginie, Martin-Duverneuil Nadine, Taly Valérie, Hélias-Rodzewicz Zofia, Emile Jean-François, Hoang-Xuan Khe, Idbaih Ahmed, Donadieu Jean

Клиническое исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Neurodegenerative (ND) complications in Langerhans cell histiocytosis (LCH) are a late-onset but dramatic sequelae for which incidence and risk factors are not well defined. Based on a national prospective registry of paediatric LCH patients, we determined the incidence rate of clinical ND LCH (cND-LCH) and analysed risk factors, taking into account disease extent and molecular characteristics. Among 1897 LCH patients, 36 (1·9%) were diagnosed with a cND-LCH. The 10-year cumulative incidence of cND-LCH was 4·1%. cND-LCH typically affected patients previously treated for a multisystem, risk organ-negative LCH, represented in 69·4% of cND-LCH cases. Pituitary gland, skin and base skull/orbit bone lesions were more frequent (P < 0·001) in cND-LCH patients compared to those without cND-LCH (respectively 86·1% vs. 12·2%, 75·0% vs. 34·2%, and 63·9% vs. 28·4%). The 'cND susceptible patients' (n = 671) i.e., children who had experienced LCH disease with pituitary or skull base or orbit bone involvement, had a 10-year cND risk of 7·8% vs. 0% for patients who did not meet these criteria. Finally, BRAFV600E status added important information among these cND susceptible patients, with the 10-year cND risk of 33·1% if a BRAFV600E mutation was present compared to 2·9% if it was absent (P = 0·002).

Для цитирования: Héritier Sébastien, Barkaoui Mohamed-Aziz, Miron Jean, Thomas Caroline, Moshous Despina, Lambilliotte Anne, Mazingue Françoise, Kebaili Kamila, Jeziorski Eric, Plat Geneviève, Aladjidi Nathalie, Pacquement Hélène, Galambrun Claire, Brugières Laurence, Leverger Guy, Mansuy Ludovic, Paillard Catherine, Deville Anne, Pagnier Anne, Lutun Anne, Gillibert-Yvert Marion, Stephan Jean-Louis, Cohen-Aubart Fleur, Haroche Julien, Pellier Isabelle, Millot Fréderic, Gandemer Virginie, Martin-Duverneuil Nadine, Taly Valérie, Hélias-Rodzewicz Zofia, Emile Jean-François, Hoang-Xuan Khe, Idbaih Ahmed, Donadieu Jean. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.. British journal of haematology. 2018. DOI: 10.1111/bjh.15577.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.